Alnylam Pharmaceuticals (ALNY) Gains from Investment Securities (2011 - 2026)

Alnylam Pharmaceuticals has reported Gains from Investment Securities for 16 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 75.89% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (down 25.18% YoY), and the FY2025 full-year result was $21.2 million, up 127.68% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $2.4 million, down from $8.8 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $9.8 million in Q1 2025, with the low at -$7.8 million in Q3 2024.
• Historically, Gains from Investment Securities has averaged $2.6 million across 5 years, with a median of $3.1 million in 2025.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities soared 3130.3% — and 2024, when it plunged 275.6%.
• Alnylam Pharmaceuticals' Gains from Investment Securities stood at -$4.1 million in 2022, then soared by 54.01% to -$1.9 million in 2023, then surged by 598.34% to $9.3 million in 2024, then fell by 5.3% to $8.8 million in 2025, then tumbled by 73.13% to $2.4 million in 2026.
• The last three Gains from Investment Securities figures came in at $2.4 million (Q1 2026), $8.8 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.